About This Calculator

The Ipilimumab (Yervoy) Dosing Schedule Calculator is an educational resource designed for healthcare professionals to project a patient’s induction dosing schedule. This tool helps visualize the administration dates and calculated doses for the initial four cycles of therapy based on patient weight and the specific clinical indication. All calculations must be verified against official prescribing information and institutional protocols.

Calculator Outputs Explained

Upon entering the required information, the calculator will generate the following outputs for the induction phase:

• Total Ipilimumab Dose: The calculated dose in milligrams (mg) for each infusion, derived from the patient’s weight in kilograms and the selected mg/kg regimen.
• Infusion Volume: The required volume in milliliters (mL), assuming a standard Yervoy concentration of 5 mg/mL.
• Induction Schedule: A list of the four administration dates for the induction cycles, which are calculated based on a 3-week (21-day) interval from the selected start date.
• Calculation Summary: A brief overview of the inputs used for the calculation, including weight, dose regimen, and the selected indication, for quick verification.

How to Use the Calculator

1. Select Clinical Indication: Choose the appropriate indication from the dropdown menu. This selection presets the recommended dose regimen options according to FDA-approved labeling.
2. Enter Patient Weight: Input the patient’s current weight. You can toggle between kilograms (kg) and pounds (lbs); the tool will automatically convert lbs to kg for the calculation.
3. Choose Dose Regimen: Select the prescribed dose in mg/kg. A “Custom” dose option is available for investigational or off-label regimens, which requires manual input.
4. Set Start Date: Use the date picker to select the planned start date for the first infusion (Cycle 1, Day 1).
5. Calculate Schedule: Click the “Calculate Schedule” button to generate the comprehensive dosing summary and administration timeline.

Dosing Overview

Ipilimumab (Yervoy) dosing is weight-based and varies by indication. It is administered as an intravenous infusion. The standard induction course consists of four doses administered every 3 weeks. Common regimens include:

• 1 mg/kg: Used in combination with nivolumab for several indications, including advanced Renal Cell Carcinoma (RCC), metastatic Colorectal Cancer (CRC) with MSI-H/dMMR, and Malignant Pleural Mesothelioma.
• 3 mg/kg: Used for unresectable or metastatic melanoma as a monotherapy or in combination with nivolumab for Hepatocellular Carcinoma (HCC).
• 10 mg/kg: Used for the adjuvant treatment of melanoma.

Always consult the full prescribing information for specific administration details, such as infusion duration (e.g., 30 or 90 minutes) and combination therapy schedules, which may differ.

Switching Therapies

Any decision to switch a patient to or from an Ipilimumab-containing regimen should be made by a qualified oncologist. This clinical decision is based on a comprehensive assessment of disease status (progression or response), prior therapies, management of toxicities, and current evidence-based clinical guidelines.

Missed Dose Protocol

If a scheduled dose of Ipilimumab is missed, the patient’s healthcare provider should be contacted immediately for guidance. The provider will determine the appropriate course of action and may need to adjust the subsequent dosing schedule. A dose should not be administered without direct instruction from the treating physician.

Safety Alerts

Ipilimumab therapy is associated with potentially severe immune-mediated adverse reactions. Clinical vigilance is essential.

Frequently Asked Questions (FAQ)

• Does this calculator provide guidance on dose modifications for toxicity?
  No. This tool is for calculating the initial induction schedule only. Dose withholding or discontinuation due to adverse reactions must be managed according to the detailed guidelines in the full prescribing information.
• What is the concentration of Yervoy used for the volume calculation?
  The calculator assumes the standard Yervoy (ipilimumab) concentration of 5 mg/mL for determining the final infusion volume.
• How many cycles does the calculator schedule?
  The tool calculates the standard 4-dose induction phase. It does not provide information on maintenance therapy, which may follow induction depending on the specific indication and regimen.
• Does the tool provide dosing information for combination agents like Nivolumab?
  No. The calculator explicitly notes when Ipilimumab is part of a combination regimen and states that the prescriber must refer to the separate prescribing information for the other agent(s).
• What should I do if a patient’s weight changes significantly during treatment?
  Weight-based dosing should be recalculated for each infusion based on the patient’s current weight. This calculator is primarily for initial treatment planning.
• Can I use this calculator for pediatric patients?
  The safety and effectiveness of Ipilimumab in pediatric patients have not been established for all indications. Always consult the FDA label for approved pediatric uses and dosing.
• Why does the calculator show a 3-week interval for the NSCLC indication?
  While the standard Ipilimumab/Nivolumab combination for NSCLC may be administered every 6 weeks, the tool projects a consistent 3-week interval for the schedule calculation. The accompanying note clarifies this assumption, and prescribers must follow the official protocol.
• Is there a maximum (capped) dose for Ipilimumab?
  The prescribing information does not specify a maximum dose; dosing is strictly weight-based. However, clinical trial or institutional protocols may have dose caps. This calculator does not apply any dose capping.

References

1. YERVOY® (ipilimumab) Prescribing Information. U.S. Food and Drug Administration. Revised: 10/2022. Accessed October 2023.
2. Yervoy (ipilimumab) for Healthcare Professionals. Bristol Myers Squibb. Accessed October 2023.
3. Yervoy (ipilimumab) European Public Assessment Report (EPAR). European Medicines Agency. Accessed October 2023.
4. Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. N Engl J Med. 2020; 382:20. Accessed October 2023.